SlideShare a Scribd company logo
TWO COMPARTMENT MODEL
• There are several possible two-compartment models
• By convention, compartment 1 is the central compartment and
compartment 2 is the tissue compartment.
• The rate constants k 12 and k 21 represent the first-order rate transfer
constants for the movement of drug from compartment 1 to compartment
2 (k 12 ) and from compartment 2 to compartment 1 (k 21 ).
• The transfer constants are sometimes termed microconstants , and their
values cannot be estimated directly.
• Most two-compartment models assume that elimination occurs from the
central compartment model, unless other information about the drug is
known.
• Drug elimination is presumed to occur from the central compartment,
because the major sites of drug elimination (renal excretion and hepatic
drug metabolism) occur in organs, such as the kidney and liver, which are
highly perfused with blood.
• The plasma level-time curve for a drug that follows a two-compartment
model may be divided into two parts:
• distribution phase and
• an elimination phase.
• The two-compartment model assumes that, at t = 0, no drug is in the
tissue compartment. After an IV bolus injection, drug equilibrates rapidly
in the central compartment.
• The distribution phase of the curve represents the initial, more rapid
decline of drug from the central compartment into the tissue
compartment. (a)
• Although drug elimination and distribution occur concurrently during the
distribution phase, there is a net transfer of drug from the central
compartment to the tissue compartment.
• The fraction of drug in the tissue compartment during the distribution
phase increases up to a maximum in a given tissue, whose value may be
greater or less than the plasma drug concentration
• At maximum tissue concentrations, the rate of drug entry
into the tissue equals the rate of drug exit from the tissue.
• The fraction of drug in the tissue compartment is now in
equilibrium (distribution equilibrium ) with the fraction of
drug in the central compartment , and the drug
concentrations in both the central and tissue
compartments decline in parallel and more slowly
compared to the distribution phase.
• This decline is a first-order process and is called the
elimination phase or the beta phase. Since plasma and
tissue concentrations decline in parallel, plasma drug
concentrations provide some indication of the
concentration of drug in the tissue. (b)
The equation 4.6 can be written as :
Apparent Volumes of Distribution
• In multiple-compartment kinetics, such as the
two compartment model, several volumes of
distribution can be calculated.
• Volumes of distribution generally reflect the
extent of drug distribution in the body on a
relative basis, and the calculations depend on
the availability of data.
VOLUME OF THE CENTRAL COMPARTMENT
• The volume of the central compartment is useful for
determining the drug concentration directly after an IV
injection into the body. In clinical pharmacy, this
volume is also referred to as V i or the initial volume of
distribution as the drug distributes within the plasma
and other accessible body fluids.
• This volume is generally smaller than the terminal
volume of distribution after drug distribution to tissue
is completed. The volume of the central compartment
is generally greater than 3 L, which is the volume of the
plasma fluid for an average adult.
• For many polar drugs, an initial volume of 7-10 L may
be interpreted as rapid drug distribution within the
plasma and some extracellular fluids.
APPARENT VOLUME OF DISTRIBUTION AT
STEADY STATE
• At steady-state conditions, the rate of drug
entry into the tissue compartment from the
central compartment is equal to the rate of
drug exit from the tissue compartment into
the central compartment.
• These rates of drug transfer are described by
the following expressions
The amount of drug in the central
compartment is Dp, is equal to Vd Cp
hence upon sustitution:
The total amount of drug in the body at steady state is equal to the sum of
the amount of drug in the tissue compartment, D t , and the amount of drug
in the central compartment, D p . Therefore, the apparent volume of drug at
steady state (V D )ss may be calculated by dividing the total amount of drug in
the body by the concentration of drug in the central compartment at steady
state:
EXTRAPOLATED VOLUME OF
DISTRIBUTION:
The extrapolated volume of distribution (V D )exp is
calculated by the following equation:
•where B is the y intercept obtained by extrapolation of
the b phase of the plasma level curve to the y axis .
Because the y intercept is a hybrid constant, as shown
by Equation 4.14
(V D )exp may also be calculated by the following
expression:
VOLUME OF DISTRIBUTION BY AREA
• The volume of distribution by area (V D )area , also
known as (V D ) , is obtained through calculations
similar to those used to find V p , except that the rate
constant b is used instead of the overall elimination
rate constant k .
• (V D ) is often calculated from total body clearance
divided by b and is influenced by drug elimination in
the beta, or b phase. Reduced drug clearance from the
body may increase AUC, such that (V D ) is either
reduced or unchanged depending on the value of b , as
shown by Equation 4.35.
Because total body clearance is equal to D 0 /[AUC] from zero to
infinity , (V D ) may be expressed in terms of clearance and the
rate constant b :
Significance of the Volumes of
Distribution
• (V D ) is affected by changes in the overall
elimination rate (ie, change in k ) and by
change in total body clearance of the drug.
• After the drug is distributed, the total amount
of drug in the body during the elimination of b
phase is calculated by using (V D ) .
V p is sometimes called the initial volume of distribution and is useful in
the calculation of drug clearance. The
magnitudes of the various apparent volumes of distribution have the
following relationships to each other:
Calculation of another V D , (V D )ss , is possible in multiple dosing or infusion. (V D )ss is
much larger than V p ; it approximates (V D ) but differs somewhat in value, depending
on the transfer constants.
Drug in the Tissue Compartment
• The apparent volume of the tissue
compartment (V t ) is a conceptual volume
only and does not represent true anatomic
volumes. The V t may be calculated from
knowledge of the transfer rate constants and
V p
• The calculation of the amount of drug in the
tissue compartment does not entail the use of V t
. Calculation of the amount of drug in the tissue
compartment provides an estimate for drug
accumulation in the tissues of the body.
• This information is vital in estimating chronic
toxicity and relating the duration of
pharmacologic activity to dose.
• Tissue compartment drug concentration is an
average estimate of the tissue pool and does not
mean that all tissues have this concentration.
• The drug concentration in a tissue biopsy will
provide an estimate for drug in that tissue
sample.
• Due to differences in blood flow and drug
partitioning into the tissue, and heterogenicity,
even a biopsy from the same tissue may have
different drug concentrations.
• Together with V p and C p , which calculate the
amount of drug in the plasma, the compartment
model provides mass balance information.
• Moreover, the pharmacodynamic activity may
correlate better with the tissue drug
concentration-time curve
To calculate the
amount of drug in the tissue compartment D t , the
following expression is used:
Drug Clearance
• The definition of clearance of a drug that follows
a two-compartment model is similar to that of
the one compartment model.
• Clearance is the volume of plasma that is cleared
of drug per unit time. Clearance may be
calculated without consideration of the
compartment model.
• Thus, clearance may be viewed as a physiologic
concept for drug removal, even though the
development of clearance is rooted in classical
pharmacokinetics
• Clearance is often calculated by a noncompartmental
approach, in which the bolus IV dose is divided by the
area under the plasma-time concentration curve from
zero to infinity.
• In evaluating the [AUC]from zero to infinity early time
points must be collected frequently to observe the
rapid decline in drug concentrations (distribution
phase) for drugs with multicompartment
pharmacokinetics.
• In the calculation of clearance using the
noncompartmental approach, underestimating the
area can inflate the calculated value of clearance.
Elimination Rate Constant
• In the two-compartment model (IV administration), the
elimination rate constant, k , represents the elimination of
drug from the central compartment, whereas b represents
drug elimination during the beta or elimination phase, when
distribution is mostly complete.
• Because of redistribution of drug out of the tissue
compartment, the plasma-drug level curve declines more
slowly in the b phase.
• Hence b is smaller than k ; thus k is a true elimination
constant, whereas b is a hybrid elimination rate constant that
is influenced by the rate of transfer of drug in and out of the
tissue compartment.
• When it is impractical to determine k , b is calculated from the
b slope.
THANKYOU

More Related Content

What's hot

Physics of tablet compression
Physics of tablet compressionPhysics of tablet compression
Physics of tablet compression
Mahadev Birajdar
 
Dissolution apparatus
Dissolution apparatusDissolution apparatus
Dissolution apparatus
Pankaj Verma
 
IN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATIONIN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATION
N Anusha
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kinetics
Sujit Patel
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALS
Divya Pushp
 
Supac
Supac Supac
Rate limiting steps in drug absorption
Rate limiting steps in drug absorptionRate limiting steps in drug absorption
Rate limiting steps in drug absorption
C Prakash
 
Stability testing
Stability testingStability testing
Stability testingGaurav Kr
 
In vitro Dissolution Testing Models
In vitro Dissolution Testing ModelsIn vitro Dissolution Testing Models
In vitro Dissolution Testing Models
Ameer Ahmed
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
Sachin G
 
Bioequivalence 112070804009
Bioequivalence  112070804009Bioequivalence  112070804009
Bioequivalence 112070804009Patel Parth
 
One compartment model IV Infusion
One compartment model IV InfusionOne compartment model IV Infusion
One compartment model IV Infusion
LakshmiChandran20
 
Dissolution Testing Apparatus
Dissolution Testing ApparatusDissolution Testing Apparatus
Dissolution Testing Apparatus
Sourav Kar
 
DISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUSDISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUS
Bushra S
 
IPQC for capsule.
IPQC for capsule.IPQC for capsule.
IPQC for capsule.
ganpat420
 
PHARMACEUTICAL VALIDATION
 PHARMACEUTICAL  VALIDATION PHARMACEUTICAL  VALIDATION
PHARMACEUTICAL VALIDATION
SACHIN C P
 
Formulation and evaluation of tdds
Formulation and evaluation of tddsFormulation and evaluation of tdds
Formulation and evaluation of tdds
Pankaj Verma
 
pharmacokinetic of iv infusion
pharmacokinetic of iv infusionpharmacokinetic of iv infusion
pharmacokinetic of iv infusionDr.saqib habib
 
Biowaivers
Biowaivers Biowaivers
one compartment open model
one compartment open modelone compartment open model
one compartment open model
SUJITHA MARY
 

What's hot (20)

Physics of tablet compression
Physics of tablet compressionPhysics of tablet compression
Physics of tablet compression
 
Dissolution apparatus
Dissolution apparatusDissolution apparatus
Dissolution apparatus
 
IN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATIONIN VITRO - IN VIVO CORRELATION
IN VITRO - IN VIVO CORRELATION
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kinetics
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALS
 
Supac
Supac Supac
Supac
 
Rate limiting steps in drug absorption
Rate limiting steps in drug absorptionRate limiting steps in drug absorption
Rate limiting steps in drug absorption
 
Stability testing
Stability testingStability testing
Stability testing
 
In vitro Dissolution Testing Models
In vitro Dissolution Testing ModelsIn vitro Dissolution Testing Models
In vitro Dissolution Testing Models
 
Generic drugs product development
Generic drugs product developmentGeneric drugs product development
Generic drugs product development
 
Bioequivalence 112070804009
Bioequivalence  112070804009Bioequivalence  112070804009
Bioequivalence 112070804009
 
One compartment model IV Infusion
One compartment model IV InfusionOne compartment model IV Infusion
One compartment model IV Infusion
 
Dissolution Testing Apparatus
Dissolution Testing ApparatusDissolution Testing Apparatus
Dissolution Testing Apparatus
 
DISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUSDISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUS
 
IPQC for capsule.
IPQC for capsule.IPQC for capsule.
IPQC for capsule.
 
PHARMACEUTICAL VALIDATION
 PHARMACEUTICAL  VALIDATION PHARMACEUTICAL  VALIDATION
PHARMACEUTICAL VALIDATION
 
Formulation and evaluation of tdds
Formulation and evaluation of tddsFormulation and evaluation of tdds
Formulation and evaluation of tdds
 
pharmacokinetic of iv infusion
pharmacokinetic of iv infusionpharmacokinetic of iv infusion
pharmacokinetic of iv infusion
 
Biowaivers
Biowaivers Biowaivers
Biowaivers
 
one compartment open model
one compartment open modelone compartment open model
one compartment open model
 

Similar to TWO COMPARTMENT MODEL.pptx

Week 4- the two open compartment
Week 4- the two open compartmentWeek 4- the two open compartment
Week 4- the two open compartment
lichlmh
 
quantitative pharmacokinetics material.pptx
quantitative pharmacokinetics material.pptxquantitative pharmacokinetics material.pptx
quantitative pharmacokinetics material.pptx
bryanosas2000
 
lecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptxlecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptx
WaqasAhmad535
 
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolusPharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Areej Abu Hanieh
 
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolusPharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Areej Abu Hanieh
 
anshu two compartment model 2.pptx
anshu two compartment model 2.pptxanshu two compartment model 2.pptx
anshu two compartment model 2.pptx
Anshulvishwakarma10
 
3.3 Multi compartment models.pptx
3.3 Multi compartment models.pptx3.3 Multi compartment models.pptx
3.3 Multi compartment models.pptx
Neha Dand
 
Pharmacokinetic parameters
Pharmacokinetic parametersPharmacokinetic parameters
Pharmacokinetic parameters
DeepakPandey379
 
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptxCO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
Samwel Samwel
 
iv infusions.pptx
iv infusions.pptxiv infusions.pptx
iv infusions.pptx
MuhammadAhmadPharmD
 
one compartment open model
one compartment open model one compartment open model
one compartment open model
NadiaSraboni
 
1 compartment model IV bolus administration equation
1 compartment model IV bolus administration equation1 compartment model IV bolus administration equation
1 compartment model IV bolus administration equation
Prabhjot Singh Bajwa
 
1612188029641020.pptx
1612188029641020.pptx1612188029641020.pptx
1612188029641020.pptx
MuhannadOmer
 
Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1
BhushanSurana2
 
4_2018_11_05!08_27_52_PM.pdf
4_2018_11_05!08_27_52_PM.pdf4_2018_11_05!08_27_52_PM.pdf
4_2018_11_05!08_27_52_PM.pdf
MrAlex28
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
Usha Prakash
 
Drug Distribution & Factors Affecting Distribution
Drug Distribution & Factors Affecting DistributionDrug Distribution & Factors Affecting Distribution
Drug Distribution & Factors Affecting Distribution
Vijay Kevlani
 

Similar to TWO COMPARTMENT MODEL.pptx (20)

Week 4- the two open compartment
Week 4- the two open compartmentWeek 4- the two open compartment
Week 4- the two open compartment
 
quantitative pharmacokinetics material.pptx
quantitative pharmacokinetics material.pptxquantitative pharmacokinetics material.pptx
quantitative pharmacokinetics material.pptx
 
lecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptxlecture 4 Clinical pharmacokinetics.pptx
lecture 4 Clinical pharmacokinetics.pptx
 
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolusPharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
Pharmacokinetics / Biopharmaceutics - Multi compartment IV bolus
 
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolusPharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolus
 
anshu two compartment model 2.pptx
anshu two compartment model 2.pptxanshu two compartment model 2.pptx
anshu two compartment model 2.pptx
 
3.3 Multi compartment models.pptx
3.3 Multi compartment models.pptx3.3 Multi compartment models.pptx
3.3 Multi compartment models.pptx
 
Pharmacokinetic parameters
Pharmacokinetic parametersPharmacokinetic parameters
Pharmacokinetic parameters
 
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptxCO1_L10_ Introduction to Pharmacology and Therapeutics  Part 3.pptx
CO1_L10_ Introduction to Pharmacology and Therapeutics Part 3.pptx
 
iv infusions.pptx
iv infusions.pptxiv infusions.pptx
iv infusions.pptx
 
one compartment open model
one compartment open model one compartment open model
one compartment open model
 
1 compartment model IV bolus administration equation
1 compartment model IV bolus administration equation1 compartment model IV bolus administration equation
1 compartment model IV bolus administration equation
 
1612188029641020.pptx
1612188029641020.pptx1612188029641020.pptx
1612188029641020.pptx
 
Kinetika En 2002
Kinetika En 2002Kinetika En 2002
Kinetika En 2002
 
Kinetika En 2002
Kinetika En 2002Kinetika En 2002
Kinetika En 2002
 
Multicompartment Models
Multicompartment ModelsMulticompartment Models
Multicompartment Models
 
Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1Clinical pharmacokinetics & pharmacodynamics 1
Clinical pharmacokinetics & pharmacodynamics 1
 
4_2018_11_05!08_27_52_PM.pdf
4_2018_11_05!08_27_52_PM.pdf4_2018_11_05!08_27_52_PM.pdf
4_2018_11_05!08_27_52_PM.pdf
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Drug Distribution & Factors Affecting Distribution
Drug Distribution & Factors Affecting DistributionDrug Distribution & Factors Affecting Distribution
Drug Distribution & Factors Affecting Distribution
 

Recently uploaded

Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
AzmatAli747758
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)
rosedainty
 
PART A. Introduction to Costumer Service
PART A. Introduction to Costumer ServicePART A. Introduction to Costumer Service
PART A. Introduction to Costumer Service
PedroFerreira53928
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxStudents, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
EduSkills OECD
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
Vivekanand Anglo Vedic Academy
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
Vivekanand Anglo Vedic Academy
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
joachimlavalley1
 

Recently uploaded (20)

Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)
 
PART A. Introduction to Costumer Service
PART A. Introduction to Costumer ServicePART A. Introduction to Costumer Service
PART A. Introduction to Costumer Service
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptxStudents, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
Students, digital devices and success - Andreas Schleicher - 27 May 2024..pptx
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
The French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free downloadThe French Revolution Class 9 Study Material pdf free download
The French Revolution Class 9 Study Material pdf free download
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
 
Additional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdfAdditional Benefits for Employee Website.pdf
Additional Benefits for Employee Website.pdf
 

TWO COMPARTMENT MODEL.pptx

  • 2. • There are several possible two-compartment models • By convention, compartment 1 is the central compartment and compartment 2 is the tissue compartment. • The rate constants k 12 and k 21 represent the first-order rate transfer constants for the movement of drug from compartment 1 to compartment 2 (k 12 ) and from compartment 2 to compartment 1 (k 21 ). • The transfer constants are sometimes termed microconstants , and their values cannot be estimated directly. • Most two-compartment models assume that elimination occurs from the central compartment model, unless other information about the drug is known. • Drug elimination is presumed to occur from the central compartment, because the major sites of drug elimination (renal excretion and hepatic drug metabolism) occur in organs, such as the kidney and liver, which are highly perfused with blood.
  • 3.
  • 4. • The plasma level-time curve for a drug that follows a two-compartment model may be divided into two parts: • distribution phase and • an elimination phase. • The two-compartment model assumes that, at t = 0, no drug is in the tissue compartment. After an IV bolus injection, drug equilibrates rapidly in the central compartment. • The distribution phase of the curve represents the initial, more rapid decline of drug from the central compartment into the tissue compartment. (a) • Although drug elimination and distribution occur concurrently during the distribution phase, there is a net transfer of drug from the central compartment to the tissue compartment. • The fraction of drug in the tissue compartment during the distribution phase increases up to a maximum in a given tissue, whose value may be greater or less than the plasma drug concentration
  • 5.
  • 6. • At maximum tissue concentrations, the rate of drug entry into the tissue equals the rate of drug exit from the tissue. • The fraction of drug in the tissue compartment is now in equilibrium (distribution equilibrium ) with the fraction of drug in the central compartment , and the drug concentrations in both the central and tissue compartments decline in parallel and more slowly compared to the distribution phase. • This decline is a first-order process and is called the elimination phase or the beta phase. Since plasma and tissue concentrations decline in parallel, plasma drug concentrations provide some indication of the concentration of drug in the tissue. (b)
  • 7.
  • 8.
  • 9.
  • 10. The equation 4.6 can be written as :
  • 11. Apparent Volumes of Distribution • In multiple-compartment kinetics, such as the two compartment model, several volumes of distribution can be calculated. • Volumes of distribution generally reflect the extent of drug distribution in the body on a relative basis, and the calculations depend on the availability of data.
  • 12. VOLUME OF THE CENTRAL COMPARTMENT • The volume of the central compartment is useful for determining the drug concentration directly after an IV injection into the body. In clinical pharmacy, this volume is also referred to as V i or the initial volume of distribution as the drug distributes within the plasma and other accessible body fluids. • This volume is generally smaller than the terminal volume of distribution after drug distribution to tissue is completed. The volume of the central compartment is generally greater than 3 L, which is the volume of the plasma fluid for an average adult. • For many polar drugs, an initial volume of 7-10 L may be interpreted as rapid drug distribution within the plasma and some extracellular fluids.
  • 13.
  • 14.
  • 15. APPARENT VOLUME OF DISTRIBUTION AT STEADY STATE • At steady-state conditions, the rate of drug entry into the tissue compartment from the central compartment is equal to the rate of drug exit from the tissue compartment into the central compartment. • These rates of drug transfer are described by the following expressions
  • 16.
  • 17. The amount of drug in the central compartment is Dp, is equal to Vd Cp hence upon sustitution:
  • 18. The total amount of drug in the body at steady state is equal to the sum of the amount of drug in the tissue compartment, D t , and the amount of drug in the central compartment, D p . Therefore, the apparent volume of drug at steady state (V D )ss may be calculated by dividing the total amount of drug in the body by the concentration of drug in the central compartment at steady state:
  • 19. EXTRAPOLATED VOLUME OF DISTRIBUTION: The extrapolated volume of distribution (V D )exp is calculated by the following equation:
  • 20. •where B is the y intercept obtained by extrapolation of the b phase of the plasma level curve to the y axis . Because the y intercept is a hybrid constant, as shown by Equation 4.14 (V D )exp may also be calculated by the following expression:
  • 21. VOLUME OF DISTRIBUTION BY AREA • The volume of distribution by area (V D )area , also known as (V D ) , is obtained through calculations similar to those used to find V p , except that the rate constant b is used instead of the overall elimination rate constant k . • (V D ) is often calculated from total body clearance divided by b and is influenced by drug elimination in the beta, or b phase. Reduced drug clearance from the body may increase AUC, such that (V D ) is either reduced or unchanged depending on the value of b , as shown by Equation 4.35.
  • 22.
  • 23. Because total body clearance is equal to D 0 /[AUC] from zero to infinity , (V D ) may be expressed in terms of clearance and the rate constant b :
  • 24. Significance of the Volumes of Distribution • (V D ) is affected by changes in the overall elimination rate (ie, change in k ) and by change in total body clearance of the drug. • After the drug is distributed, the total amount of drug in the body during the elimination of b phase is calculated by using (V D ) .
  • 25. V p is sometimes called the initial volume of distribution and is useful in the calculation of drug clearance. The magnitudes of the various apparent volumes of distribution have the following relationships to each other: Calculation of another V D , (V D )ss , is possible in multiple dosing or infusion. (V D )ss is much larger than V p ; it approximates (V D ) but differs somewhat in value, depending on the transfer constants.
  • 26. Drug in the Tissue Compartment • The apparent volume of the tissue compartment (V t ) is a conceptual volume only and does not represent true anatomic volumes. The V t may be calculated from knowledge of the transfer rate constants and V p
  • 27. • The calculation of the amount of drug in the tissue compartment does not entail the use of V t . Calculation of the amount of drug in the tissue compartment provides an estimate for drug accumulation in the tissues of the body. • This information is vital in estimating chronic toxicity and relating the duration of pharmacologic activity to dose. • Tissue compartment drug concentration is an average estimate of the tissue pool and does not mean that all tissues have this concentration.
  • 28. • The drug concentration in a tissue biopsy will provide an estimate for drug in that tissue sample. • Due to differences in blood flow and drug partitioning into the tissue, and heterogenicity, even a biopsy from the same tissue may have different drug concentrations. • Together with V p and C p , which calculate the amount of drug in the plasma, the compartment model provides mass balance information. • Moreover, the pharmacodynamic activity may correlate better with the tissue drug concentration-time curve
  • 29. To calculate the amount of drug in the tissue compartment D t , the following expression is used:
  • 30. Drug Clearance • The definition of clearance of a drug that follows a two-compartment model is similar to that of the one compartment model. • Clearance is the volume of plasma that is cleared of drug per unit time. Clearance may be calculated without consideration of the compartment model. • Thus, clearance may be viewed as a physiologic concept for drug removal, even though the development of clearance is rooted in classical pharmacokinetics
  • 31. • Clearance is often calculated by a noncompartmental approach, in which the bolus IV dose is divided by the area under the plasma-time concentration curve from zero to infinity. • In evaluating the [AUC]from zero to infinity early time points must be collected frequently to observe the rapid decline in drug concentrations (distribution phase) for drugs with multicompartment pharmacokinetics. • In the calculation of clearance using the noncompartmental approach, underestimating the area can inflate the calculated value of clearance.
  • 32.
  • 33. Elimination Rate Constant • In the two-compartment model (IV administration), the elimination rate constant, k , represents the elimination of drug from the central compartment, whereas b represents drug elimination during the beta or elimination phase, when distribution is mostly complete. • Because of redistribution of drug out of the tissue compartment, the plasma-drug level curve declines more slowly in the b phase. • Hence b is smaller than k ; thus k is a true elimination constant, whereas b is a hybrid elimination rate constant that is influenced by the rate of transfer of drug in and out of the tissue compartment. • When it is impractical to determine k , b is calculated from the b slope.